Cargando…

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma

Detalles Bibliográficos
Autores principales:	Ma, Xuhui, Wu, Shanshan, Li, Botai, Zhang, Qianqian, Zhang, Jianming, Liu, Wenming, Yan, Hexin, Bernards, René, Qin, Wenxin, Wang, Cun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399229/ https://www.ncbi.nlm.nih.gov/pubmed/35999219 http://dx.doi.org/10.1038/s41421-022-00425-y

Ejemplares similares

Cabozantinib‐induced renal thrombotic microangiopathy
por: La Manna, Gaetano, et al.
Publicado: (2017)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
por: Kelley, Robin K., et al.
Publicado: (2020)

Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
por: Shang, Runze, et al.
Publicado: (2021)

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
por: Storandt, Michael H., et al.
Publicado: (2022)

Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models
por: Lang, Julie, et al.
Publicado: (2022)

Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
por: Zhang, Qing, et al.
Publicado: (2017)

A Targetable Molecular Chaperone Hsp27 Confers Aggressiveness in Hepatocellular Carcinoma
por: Zhang, Yurong, et al.
Publicado: (2016)

Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations
por: Debaillon Vesque, Audrey, et al.
Publicado: (2020)

Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives
por: Trojan, Jörg
Publicado: (2020)

Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis
por: Shlomai, Amir, et al.
Publicado: (2019)

Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models
por: Deng, Shanshan, et al.
Publicado: (2021)

Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
por: Schwartz, Gabriel, et al.
Publicado: (2020)

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
por: Rathi, Nityam, et al.
Publicado: (2020)

Impact of Cabozantinib Exposure on Proteinuria and Muscle Toxicity in Patients with Unresectable Hepatocellular Carcinoma
por: Okubo, Hironao, et al.
Publicado: (2022)

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
por: Liu, Si-Yang Maggie, et al.
Publicado: (2023)

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
por: Yu, Xiaoqi, et al.
Publicado: (2022)

The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges
por: D’Alessio, Antonio, et al.
Publicado: (2021)

Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade
por: Kelley, Robin Kate, et al.
Publicado: (2021)

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study
por: Kudo, Masatoshi, et al.
Publicado: (2021)

Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification
por: Sang, Yun Beom, et al.
Publicado: (2023)

Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling
por: Nguyen, Holly M., et al.
Publicado: (2013)

Association between Angiotensin Blockade and Incidence of Influenza in the United Kingdom
por: Chung, Sheng-Chia, et al.
Publicado: (2020)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019)

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study
por: Kelley, R. K., et al.
Publicado: (2017)

Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma
por: Nguyen, Linh, et al.
Publicado: (2019)

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
por: Wong, Jeffrey Sum-Lung, et al.
Publicado: (2021)

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
por: Ho, Won Jin, et al.
Publicado: (2021)

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
por: Zhang, Shuming, et al.
Publicado: (2023)

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
por: Zhang, Shuming, et al.
Publicado: (2023)

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second- or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a phase 2 randomised controlled trial
por: Neal, Joel W., et al.
Publicado: (2016)

Comparison of irreversible electroporation ablation in mice livers with or without a thermally controlled algorithm
por: Zhang, Ke, et al.
Publicado: (2022)

Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma
por: Mi, Haoyang, et al.
Publicado: (2022)

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
Publicado: (2014)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Modulation of cabozantinib efficacy by the prostate tumor microenvironment
por: Tripathi, Manisha, et al.
Publicado: (2017)

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib
por: Scirocchi, Fabio, et al.
Publicado: (2021)

Regression of Intracranial Meningiomas Following Treatment with Cabozantinib
por: Kotecha, Rupesh, et al.
Publicado: (2021)

Medical Conference
por: Newman, E. A. P.
Publicado: (1913)

Use of Cabozantinib in a Patient With EGFR-Mutated Non–Small-Cell Lung Cancer Harboring Acquired CCDC6-RET Fusion
por: Chae, Young Kwang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fl562jo69dpcs8pnpq1uju8eo4